Have a feature idea you'd love to see implemented?
Let us know!
INZY Inozyme Pharma Inc
Price (delayed)
$2.69
Market cap
$172.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.56
Enterprise value
$194.71M
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in
Highlights
The quick ratio has plunged by 54% YoY and by 23% from the previous quarter
The equity has declined by 48% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of INZY
Market
Valuations
Earnings
Shares outstanding
64.24M
Market cap
$172.81M
Enterprise value
$194.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$89.03M
EBITDA
-$87.71M
Free cash flow
-$91.36M
Per share
Balance sheet
Liquidity
EPS
-$1.56
Free cash flow per share
-$1.44
Book value per share
$1.32
Revenue per share
$0
TBVPS
$2.27
Total assets
$143.36M
Total liabilities
$60.57M
Debt
$46.79M
Equity
$82.79M
Working capital
$122.59M
Debt to equity
0.57
Current ratio
7.68
Quick ratio
7.19
Net debt/EBITDA
-0.25
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57%
Return on equity
-88.4%
Return on invested capital
-50.4%
Return on capital employed
-71.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INZY stock price
How has the Inozyme Pharma stock price performed over time
Intraday
-3.58%
1 week
-21.57%
1 month
-49.05%
1 year
-29.77%
YTD
-36.85%
QTD
-48.57%
Financial performance
How have Inozyme Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$99.67M
Net income
-$96.49M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 42% YoY and by 9% QoQ
INZY's operating income is down by 38% year-on-year and by 7% since the previous quarter
Growth
What is Inozyme Pharma's growth rate over time
Valuation
What is Inozyme Pharma stock price valuation
P/E
N/A
P/B
2.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INZY's EPS is down by 7% since the previous quarter and by 7% year-on-year
The equity has declined by 48% year-on-year and by 12% since the previous quarter
The price to book (P/B) is 36% lower than the last 4 quarters average of 3.2 and 11% lower than the 5-year quarterly average of 2.3
Efficiency
How efficient is Inozyme Pharma business performance
INZY's ROE has dropped by 58% year-on-year and by 28% since the previous quarter
The company's return on assets fell by 33% YoY and by 19% QoQ
The company's return on invested capital fell by 14% QoQ
Dividends
What is INZY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INZY.
Financial health
How did Inozyme Pharma financials performed over time
Inozyme Pharma's total assets is 137% higher than its total liabilities
The quick ratio has plunged by 54% YoY and by 23% from the previous quarter
Inozyme Pharma's current ratio has plunged by 53% YoY and by 22% from the previous quarter
The company's debt is 43% lower than its equity
The debt to equity has soared by 171% YoY and by 16% from the previous quarter
The equity has declined by 48% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.